"Pancreatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Descriptor ID |
D010190
|
| MeSH Number(s) |
C04.588.274.761 C04.588.322.475 C06.301.761 C06.689.667 C19.344.421
|
| Concept/Terms |
Pancreatic Neoplasms- Pancreatic Neoplasms
- Neoplasm, Pancreatic
- Pancreatic Neoplasm
- Pancreas Neoplasms
- Neoplasm, Pancreas
- Neoplasms, Pancreas
- Pancreas Neoplasm
- Neoplasms, Pancreatic
Cancer of Pancreas- Cancer of Pancreas
- Pancreas Cancers
- Pancreas Cancer
- Cancer, Pancreas
- Cancers, Pancreas
- Pancreatic Cancer
- Cancer, Pancreatic
- Cancers, Pancreatic
- Pancreatic Cancers
- Cancer of the Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Pancreatic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Pancreatic Neoplasms".
This graph shows the total number of publications written about "Pancreatic Neoplasms" by people in this website by year, and whether "Pancreatic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 3 | 0 | 3 |
| 1994 | 9 | 4 | 13 |
| 1995 | 4 | 2 | 6 |
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 1 | 3 |
| 1998 | 1 | 1 | 2 |
| 1999 | 3 | 1 | 4 |
| 2000 | 2 | 1 | 3 |
| 2001 | 6 | 0 | 6 |
| 2002 | 5 | 7 | 12 |
| 2003 | 1 | 0 | 1 |
| 2004 | 5 | 1 | 6 |
| 2005 | 22 | 3 | 25 |
| 2006 | 10 | 3 | 13 |
| 2007 | 17 | 1 | 18 |
| 2008 | 19 | 3 | 22 |
| 2009 | 16 | 3 | 19 |
| 2010 | 17 | 2 | 19 |
| 2011 | 18 | 4 | 22 |
| 2012 | 8 | 2 | 10 |
| 2013 | 18 | 3 | 21 |
| 2014 | 21 | 1 | 22 |
| 2015 | 16 | 2 | 18 |
| 2016 | 25 | 1 | 26 |
| 2017 | 20 | 4 | 24 |
| 2018 | 16 | 1 | 17 |
| 2019 | 26 | 3 | 29 |
| 2020 | 14 | 2 | 16 |
| 2021 | 5 | 1 | 6 |
| 2022 | 14 | 0 | 14 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pancreatic Neoplasms" by people in Profiles.
-
Novel treatment strategy of targeting epigenetic dysregulation in pancreatic neuroendocrine tumors. Surgery. 2023 Apr; 173(4):1045-1051.
-
Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma. JCO Precis Oncol. 2023 Jan; 7:e2200196.
-
All Together Now: Standardization of Nomenclature for Neuroendocrine Neoplasms across Multiple Organs. Surg Pathol Clin. 2023 Mar; 16(1):131-150.
-
Extended postoperative thromboprophylaxis after pancreatic resection for pancreatic cancer is associated with decreased risk of venous thromboembolism in the minimally invasive approach. J Surg Oncol. 2023 Mar; 127(3):413-425.
-
Editorial Comment: Radiomics and Pneumonia-Type Invasive Mucinous Carcinoma-A Future Promise. AJR Am J Roentgenol. 2023 02; 220(2):235.
-
Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer. Int J Mol Sci. 2022 Sep 29; 23(19).
-
Standardization of MRI Screening and Reporting in Individuals With Elevated Risk of Pancreatic Ductal Adenocarcinoma: Consensus Statement of the PRECEDE Consortium. AJR Am J Roentgenol. 2022 12; 219(6):903-914.
-
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. J Clin Oncol. 2022 12 01; 40(34):3929-3939.
-
Pancreatic Ductal Carcinoma Risk Associated With Hereditary Cancer-Risk Genes. J Natl Cancer Inst. 2022 07 11; 114(7):996-1002.
-
Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer. Cancer Lett. 2022 09 28; 544:215801.